Robust expression of tumor suppressor miRNA’s let-7 and miR-195 detected in plasma of Saudi female breast cancer patients

BMC Cancer

Research Article

Chafica Eltabache¹  Suad Bin Amer¹  Haya Intabli²  Amal Qattan³  Wafa Alkhayal⁴  Taher Tweigieri⁵ 

[1] Breast Cancer Research, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, P.O.Box 3354, 11211, Riyadh, Saudi Arabia;Breast Cancer Research, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, P.O.Box 3354, 11211, Riyadh, Saudi Arabia;College of Medicine, Alfaisal University, P.O.Box 50927, 11533, Riyadh, Saudi Arabia;Breast Cancer Research, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, P.O.Box 3354, 11211, Riyadh, Saudi Arabia;Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences (SMHS), George Washington University, 2600 Virginia Avenue, NW, Suite 300, 20037, Washington, DC, USA;College of Medicine, Alfaisal University, P.O.Box 50927, 11533, Riyadh, Saudi Arabia;College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia;Department of Surgery, King Faisal Specialist Hospital and Research centre, Riyadh, Saudi Arabia;Department of Oncology, King Faisal Specialist Hospital and Research centre, Riyadh, Saudi Arabia;

关键词: Circulating miRNAs;    Triple-negative breast cancer (TNBC);    Circulating biomarkers;    Plasma versus tissue;    Secretion;    FASN pathway;    ROC curves;    Cancer therapy;   

DOI  :  10.1186/s12885-017-3776-5

 received in 2017-02-27, accepted in 2017-11-13,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundFemale breast cancer is frequently diagnosed at a later stage and the leading cause of cancer deaths world-wide. Levels of cell-free circulating microRNAs (miRNAs) can potentially be used as biomarkers to measure disease progression in breast cancer patients in a non-invasive way and are therefore of high clinical value.MethodsUsing quantitative RT-PCR, circulating miRNAs were measured in blood samples collected from disease-free individuals (n = 34), triple-negative breast tumours (TNBC) (n = 36) and luminal tumours (n = 57). In addition to intergroup comparisons, plasma miRNA expression levels of all groups were analyzed against RNASeq data from cancerous breast tissue via The Cancer Genome Atlas (TCGA).ResultsA differential set of 18 miRNAs were identified in the plasma of breast cancer patients and 10 miRNAs were uniquely identified based on ROC analysis. The most striking findings revealed elevated tumor suppressor let-7 miRNA in luminal breast cancer patients, irrespective of subtype, and elevated miR-195 in plasma of TNBC breast cancer patients. In contrast, hsa-miR-195 and let-7 miRNAs were absent from cancerous TCGA tissue and strongly expressed in surrounding non-tumor tissue indicating that cancerous cells may selectively export tumor suppressor hsa-miR-195 and let-7 miRNAs in order to maintain oncogenesis.ConclusionsWhile studies have indicated that the restoration of let-7 and miR-195 may be a potential therapy for cancer, these results suggested that tumor cells may selectively export hsa-miR-195 and let-7 miRNAs thereby neutralizing their potential therapeutic effect. However, in order to facilitate earlier detection of breast cancer, blood based screening of hsa-miR-195 and let-7 may be beneficial in a female patient cohort.

【 授权许可】

CC BY   
© The Author(s). 2017